Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Gene mutation (KRAS, BRAF, PIK3CA) and clinical benefit of anti-EGFR antibody].

Nihon rinsho. Japanese journal of clinical medicine - 1 Apr 2011

Ueno Takunori, Moriwaki Toshikazu, Hyodo Ichinosuke

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal
Share to Antibodies, Monoclonal, Humanized
Share to Cetuximab
Share to Class I Phosphatidylinositol 3-Kinases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Panitumumab

Share to Phosphatidylinositol 3-Kinases

Share to Proto-Oncogene Proteins p21(ras)

Share to ras Proteins

Source

Identifiers

PMID: 22214007

Genes

BRAF
EGFR
KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Gene mutation (KRAS, BRAF, PIK3CA) and clinical benefit of anti-EGFR antibody].PMID 22214007Read ↗

[EGFR pathway and mechanism of action of tyrosine kinase inhibitors].Semantic proximity Read ↗

EGFR mutations and EGFR tyrosine kinase inhibitors.Semantic proximity Read ↗

[Anti-EGFR antibody therapy for colorectal cancer].Semantic proximity Read ↗

[BRAF inhibitor and MEK inhibitor].Semantic proximity Read ↗

[EGFR/HER1: a target life].Semantic proximity Read ↗

Personalized medicine and anti-EGFR antibody therapy in the treatment of metastatic colorectal cancer: KRAS and beyond.Semantic proximity Read ↗

[Biomarkers of Anti-EGFR Antibodies in the Treatment of Metastatic Colorectal Cancer].Semantic proximity Read ↗

EGFR pharmacogenomics: the story continues to mutate and evolve.Semantic proximity Read ↗

[Current update and testing procedures for genetic diagnosis in malignant neoplasm: additional information on pathological tests].Semantic proximity Read ↗

INTERESTing biomarker to select IDEAL patients for epidermal growth factor receptor tyrosine kinase inhibitors: yes, for EGFR mutation analysis, others, I PASS.Semantic proximity Read ↗

[Antibody therapy in cancer].Semantic proximity Read ↗

Beyond KRAS status and response to anti-EGFR therapy in metastatic colorectal cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.